Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologySix-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

In patients with advanced-stage, untreated follicular lymphoma (FL), the RELEVANCE trial demonstrated that rituximab plus chemotherapy (R-chemo) and lenalidomide plus rituximab (R2) had comparable efficacy (FL). After six years of follow-up, a report on the second interim analysis of the RELEVANCE experiment is presented here.